Bavarian Nordic AS (OCSE:BAVA) is set to release its Q3 2024 earnings on Nov 15, 2024. The consensus estimate for Q3 2024 ...

Several African and ex-Soviet countries have expressed interest in buying Russia's vaccine against smallpox and mpox viruses, ...

The vaccines the DRC currently has are manufactured by Danish drugmaker Bavarian Nordic and only intended for adults. The DRC ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...

COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders secured, ...

Is Bavarian Nordic (BVNRY) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. Bavarian Nordic is a member of our Medical group ...

Bavarian Nordic gets $63 million US government order for small pox, mpox vaccine September 24, 2024 Future of Healthcategory Bavarian says mpox vaccine approved by EU regulator for adolescents ...

One stock to keep an eye on is Bavarian Nordic (BVNRY). BVNRY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. Another notable valuation metric for BVNRY is its P/B ...